Fred Hutch’s Obliteride breaks fundraising record raising nearly $3 million

News Releases

Fred Hutch’s Obliteride breaks fundraising record raising nearly $3 million

The annual ride is now the top charity bike ride in the Northwest

SEATTLE, Oct. 19, 2017 – More than 2,000 Obliteride riders raised $2.8 million in 2017, more than any previous year, with every dollar going to lifesaving research at Fred Hutchinson Cancer Research Center. Obliteride is now the largest and most successful charity bike ride in the Pacific Northwest.

“We are grateful to all our riders, sponsors, and volunteers for making this our best year yet. The combined generosity and community engagement is emblematic of how deeply people care about finding cures for cancer, faster,” said Kelly O’Brien, vice president of Philanthropy at Fred Hutch. “We’re committed to curing cancer by 2025, and these funds go straight to work in labs across campus.”

Obliteride riders cross the finish line

Obliteride riders cross the finish line

In five years, 6,271 Obliteride riders have raised $12 million for Fred Hutch and pedaled 401,585 miles. This year, Obliteride’s top individual fundraiser raised more than $102,000 and team LEWIS & FRIENDS CERCumvent Cancer has raised $1 million in five years. Obliteride donations are accelerating research in many areas including prostate, lung and blood cancer research. They’ve also funded a revolutionary new way to diagnose chronic myeloid leukemia that is already saving lives.

“Obliteride is bigger than a ride, bigger than a weekend, and certainly bigger than Seattle,” said Andrea Gomes Morrison, Obliteride director. “Discoveries made at Fred Hutch help people all over the world, and we invite everyone to come ride with us to help cure cancer faster.”

 

Fred Hutch’s Obliteride thanks founding sponsors University Village and Sloan Foundation for their support. They are joined by many generous sponsors who make it possible for Obliteride to offer fully supported rides, an entire weekend of entertainment, and delicious meals.

 

Obliteride 2018 will take place on August 10-12. Registration opens early next year. Learn more at Obliteride.org

###

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

ABOUT OBLITERIDE

Obliteride is maniacally focused on FUNding cancer research at Fred Hutch and ultimately, ending cancer. We ride together annually, focusing on possibilities, embracing our fears and celebrating discovery. It’s fun, focused and full of energy! Learn more at www.obliteride.org.